President Trump announced a new Most-Favored-Nation (MFN) drug pricing agreement with Regeneron, the latest in a series of voluntary agreements between the administration and major pharmaceutical manufacturers. Under the agreement, state Medicaid programs would receive access to MFN pricing for Regeneron products, and Regeneron would offer its cholesterol drug Praluent through the TrumpRx platform at a discounted cash price. The White House also said Regeneron agreed to provide its newly approved gene therapy, Otarmeni, at no cost to eligible U.S. patients and to make additional U.S. research and manufacturing investments.  

The announcement reflects the Administration’s broader effort to tie drug pricing commitments to tariff relief and other manufacturer incentives, with the stated goal of bringing U.S. prices closer to those paid in other developed countries. While the agreement could lower costs for certain Medicaid drugs and some patients using TrumpRx, the overall impact remains uncertain because full deal terms have not been publicly released and savings may vary by drug, payer and patient circumstance. Some policy analysts have also cautioned that direct-to-consumer discounts may not always produce the lowest available price for patients, particularly where lower-cost generic options exist.